Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Clinical Chemistry 35: 857-860, 1989;
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rognerud, C. L.
Right arrow Articles by Ou, C. N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rognerud, C. L.
Right arrow Articles by Ou, C. N.

Clinical Chemistry, Vol 35, 857-860, Copyright © 1989 by American Association for Clinical Chemistry

Concurrent measurement of flecainide acetate and propranolol by normal- phase high-performance liquid chromatography

CL Rognerud and CN Ou
Department of Pathology, Texas Children's Hospital, Houston 77030.

This simple, isocratic, normal-phase liquid-chromatographic method concurrently measures flecainide acetate and propranolol in 100 microL of serum within 8 min. The chromatographic system consists of a Waters "Resolve" column packed with 5-microns silica spheres and a mobile phase of ammonium sulfate (10 mmol/L, pH 6.8)/methanol (22/78 by vol), pumped at 0.9 mL/min and monitored by a fluorometer (excitation at 225 nm and emission at 340 nm). After 100 microL of serum is mixed with 200 microL of the internal standard solution [N-(2-piperidylmethyl)-2,3- bis(2,2,2-trifluoroethoxy)-benzamide HCl, 2500 micrograms/L] and 200 microL of 0.2 mol/L sodium carbonate, the sample is extracted into butanol/hexane (20/80 by vol). The organic layer is separated and evaporated, and the residue is redissolved in 200 microL of methanol; 50 microL of this is injected onto the column. Relative recovery was 100% over the assay range of 25-2000 micrograms/L for flecainide and 10- 2000 micrograms/L for propranolol. Within-run CVs were less than 2% for flecainide and less than 5% for propranolol; day-to-day CVs ranged from 5.0% to 6.5% for flecainide and from 3% to 12% for propranolol.





HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1989 by the American Association for Clinical Chemistry.